Leukemia Research
Volume 33, Issue 12 , Pages 1670-1677 , December 2009

OH-2, a hyperdiploid myeloma cell line without an IGH translocation, has a complex translocation juxtaposing MYC near MAFB and the IGK locus

  • Thea Kristin Våtsveen

      Affiliations

    • Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    • Department of Pathology and Medical Genetics, St. Olavs University Hospital, Trondheim, Norway
    • Corresponding Author InformationCorresponding author at: Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, Olav Kyrres gt. 9, N-7489 Trondheim, Norway. Tel.: +47 73 59 86 60; fax: +47 73 59 88 01.
    • ,
  • Erming Tian

      Affiliations

    • Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    • ,
  • Stine H. Kresse

      Affiliations

    • Department of Tumor Biology, Radiumhospitalet, Rikshospitalet, Oslo, Norway
    • ,
  • Leonardo A. Meza-Zepeda

      Affiliations

    • Department of Tumor Biology, Radiumhospitalet, Rikshospitalet, Oslo, Norway
    • Norwegian Microarray Consortium1, Department of Molecular Biosciences, University of Oslo, Oslo, Norway
    • ,
  • Ana Gabrea

      Affiliations

    • Genetics Branch, National Cancer Institute, Bethesda, MD, USA
    • ,
  • Oleg Glebov

      Affiliations

    • Genetics Branch, National Cancer Institute, Bethesda, MD, USA
    • ,
  • Hong Yan Dai

      Affiliations

    • Department of Pathology and Medical Genetics, St. Olavs University Hospital, Trondheim, Norway
    • ,
  • Anders Sundan

      Affiliations

    • Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    • ,
  • W. Michael Kuehl

      Affiliations

    • Genetics Branch, National Cancer Institute, Bethesda, MD, USA
    • ,
  • Magne Børset

      Affiliations

    • Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    • Department of Immunology and Transfusion Medicine, St. Olavs University Hospital, Trondheim, Norway

Received 21 January 2009 ,Revised 21 January 2009 ,Accepted 2 March 2009.

References 

  1. Chng WJ, Glebov O, Bergsagel PL, Kuehl WM. Genetic events in the pathogenesis of multiple myeloma. Best Pract Res Clin Haematol. 2007;20(December (4)):571–596
  2. Fonseca R, Debes-Marun CS, Picken EB, Dewald GW, Bryant SC, Winkler JM, et al. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood. 2003;102(October (7)):2562–2567
  3. Smadja NV, Bastard C, Brigaudeau C, Leroux D, Fruchart C. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood. 2001;98(October (7)):2229–2238
  4. Gabrea A, Martelli ML, Qi Y, Roschke A, Barlogie B, Shaughnessy JD, et al. Secondary genomic rearrangements involving immunoglobulin or MYC loci show similar prevalences in hyperdiploid and nonhyperdiploid myeloma tumors. Genes Chromosome Cancer. 2008 Jul;47(7):573–590
  5. Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol. 2005;23(September (26)):6333–6338
  6. Avet-Loiseau H, Daviet A, Brigaudeau C, Callet-Bauchu E, Terre C, Lafage-Pochitaloff M, et al. Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis. Blood. 2001;97(February (3)):822–825
  7. Tiedemann RE, Gonzalez-Paz N, Kyle RA, Santana-Davila R, Price-Troska T, Van Wier SA, et al. Genetic aberrations and survival in plasma cell leukemia. Leukemia. 2008;22(5):1044–1052
  8. Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood. 2005;106(July (1)):296–303
  9. Chng WJ, Fonseca R. Cell lines of hyperdiploid myeloma, are we there yet?. Br J Haematol. 2008;140(5):579–580
  10. Borset M, Waage A, Brekke OL, Helseth E. TNF and IL-6 are potent growth factors for OH-2, a novel human myeloma cell line. Eur J Haematol. 1994;53(July (1)):31–37
  11. Jackson N, Lowe J, Ball J, Bromidge E, Ling NR, Larkins S, et al. Two new IgA1-kappa plasma cell leukaemia cell lines (JJN-1 & JJN-2) which proliferate in response to B cell stimulatory factor 2. Clin Exp Immunol. 1989;75(January (1)):93–99
  12. Fagerli UM, Holt RU, Holien T, Vaatsveen TK, Zhan F, Egeberg KW, et al. Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells. Blood. 2008;111(January (2)):806–815
  13. Ro TB, Holt RU, Brenne AT, Hjorth-Hansen H, Waage A, Hjertner O, et al. Bone morphogenetic protein-5, -6 and -7 inhibit growth and induce apoptosis in human myeloma cells. Oncogene. 2004;23(April (17)):3024–3032
  14. Sawyer JR, Roloson GJ, Bell JM, Thomas JR, Teo C, Chadduck WM. Telomeric associations in the progression of chromosome aberrations in pediatric solid tumors. Cancer Genet Cytogenet. 1996;90(August (1)):1–13
  15. Sawyer JR, Lukacs JL, Thomas EL, Swanson CM, Goosen LS, Sammartino G, et al. Multicolour spectral karyotyping identifies new translocations and a recurring pathway for chromosome loss in multiple myeloma. Br J Haematol. 2001;112(January (1)):167–174
  16. Meza-Zepeda LA, Kresse SH, Barragan-Polania AH, Bjerkehagen B, Ohnstad HO, Namlos HM, et al. Array comparative genomic hybridization reveals distinct DNA copy number differences between gastrointestinal stromal tumors and leiomyosarcomas. Cancer Res. 2006;66(September (18)):8984–8993
  17. Wang J, Meza-Zepeda LA, Kresse SH, Myklebost O. M-CGH: analysing microarray-based CGH experiments. BMC Bioinformatics. 2004;June (5):74
  18. Bergsagel PL, Chesi M, Nardini E, Brents LA, Kirby SL, Kuehl WM. Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proc Natl Acad Sci USA. 1996 Nov 26;93(24):13931–13936
  19. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, et al. The molecular classification of multiple myeloma. Blood. 2006;108(September (6)):2020–2028
  20. Dib A, Peterson TR, Raducha-Grace L, Zingone A, Zhan F, Hanamura I, et al. Paradoxical expression of INK4c in proliferative multiple myeloma tumors: bi-allelic deletion vs increased expression. Cell Div. 2006;1:23
  21. Drexler HG, Matsuo Y. Malignant hematopoietic cell lines: in vitro models for the study of multiple myeloma and plasma cell leukemia. Leuk Res. 2000;24(August (8)):681–703
  22. Chng WJ, Kumar S, Vanwier S, Ahmann G, Price-Troska T, Henderson K, et al. Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Cancer Res. 2007;67(April (7)):2982–2989
  23. Li X, Pennisi A, Zhan F, Sawyer JR, Shaughnessy JD, Yaccoby S. Establishment and exploitation of hyperdiploid and non-hyperdiploid human myeloma cell lines. Br J Haematol. 2007;138(September (6)):802–811

PII: S0145-2126(09)00109-X

doi: 10.1016/j.leukres.2009.03.001

Leukemia Research
Volume 33, Issue 12 , Pages 1670-1677 , December 2009

Article Tools

* Image Usage & Resolution